Company news

Lantern Pharma Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Lantern Pharma Expands AI Capabilities of RADR® Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors

August 27, 2023

Lantern Pharma Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT

August 13, 2023

Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights

August 8, 2023

Lantern Pharma to Report Second Quarter 2023 Operating & Financial Results on August 9, 2023 at 4: 30 p.m. ET

August 1, 2023

Lantern Pharma to Participate and Present at Multiple Upcoming Conferences

July 16, 2023

Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement of LP-284, a Novel Synthetically Lethal Drug Candidate for Non-Hodgkin’s Lymphomas

June 25, 2023

Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors

June 11, 2023

Lantern Pharma Leverages AI Platform, RADR®, to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld University

June 7, 2023

Lantern Pharma to Present at the Lytham Partners Spring 2023 Investor Conference Thursday, May 18th at 9: 00 a.m. ET

May 16, 2023

Lantern Pharma Reports First Quarter 2023 Financial Results and Operational Highlights

May 8, 2023

Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic™ Clinical Trial

May 2, 2023

Lantern Pharma to Report First Quarter 2023 Operating & Financial Results on May 9, 2023 at 4: 30 p.m. ET

May 1, 2023

Lantern Pharma Develops Top-Ranked AI Algorithms to Predict the Blood-Brain-Barrier Permeability of Any Compound

May 1, 2023

Lantern Pharma Receives Notice of Allowance for Composition of Matter Patent Covering Drug Candidate LP-284

April 12, 2023

Lantern Pharma Announces First Patient Dosed in the Phase 2 Study, Harmonic™, for LP-300 in Never Smokers with Advanced Non-Small Cell Lung Cancer

March 27, 2023

Lantern Pharma to Present at Upcoming Scientific Conferences and Webinars

March 20, 2023

Lantern Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Operational Highlights

March 19, 2023

Lantern Pharma to Present at the American Association for Cancer Research (AACR) Annual Meeting

March 14, 2023

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2022 Operating & Financial Results on March 20, 2023 at 4: 30 p.m. ET

March 12, 2023

Lantern Pharma Confirms It Had No Exposure to Silicon Valley Bank (SVB), Silvergate Bank, or Signature Bank

March 12, 2023

Lantern Pharma Announces New Data and Development Focus for LP-100 with PARP Inhibitors

March 8, 2023

Lantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality, the Powerful Mechanism of Action Behind Several of Lantern’s Drug Candidates, Featuring Zoltan Szallasi, M.D.

March 7, 2023

Lantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central Nervous System) and Brain Cancers

March 5, 2023

Lantern Pharma Expands Clinical Leadership Team to Further Advance its Ongoing and Upcoming Clinical Trials

March 1, 2023

Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of Drug Candidate TTC-352

February 26, 2023

Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product Development Roadmap for the Development of Antibody Drug Conjugates

February 14, 2023

Lantern Pharma Receives Pre-IND Feedback from the FDA, Clearing a Path for Drug Candidate LP-184’s Phase 1 Clinical Trial in Q2 2023

January 16, 2023

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in Mantle Cell Lymphoma

January 4, 2023

Lantern Pharma Announces Positive New Data for its Drug Candidate LP-284 for Mantle Cell Lymphoma (MCL) at the American Society of Hematology (ASH) 2022 Annual Meeting

December 14, 2022

Lantern Pharma Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC) at the San Antonio Breast Cancer Symposium (SABCS)

December 12, 2022

Lantern Pharma Announces Positive Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-184 for Glioblastoma at the Society for Neuro-Oncology Annual Meeting

November 21, 2022

Lantern Pharma Reports Third Quarter 2022 Financial Results and Operational Highlights

November 6, 2022

Lantern Pharma to Report Third Quarter 2022 Operating & Financial Results on November 7, 2022 at 4: 30 p.m. ET

October 30, 2022

Lantern Pharma Announces Issuance of New Patent that Strengthens Patent Portfolio for Cancer Drug Candidate LP-300

October 19, 2022

Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-284 for Mantle Cell Lymphoma at the Society of Hematologic Oncology Annual Meeting

September 22, 2022

Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-184 for Pancreatic Cancer at the AACR Special Conference for Pancreatic Cancer

September 13, 2022

Lantern Pharma Reports Second Quarter 2022 Financial Results and Operational Highlights

August 7, 2022

Lantern Pharma to Report Second Quarter 2022 Operating & Financial Results on August 8th, 2022 at 4: 30 p.m. ET

July 31, 2022

Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical Trial, Harmonic™, for LP-300 in Never Smokers with Non-Small Cell Lung Cancer

July 13, 2022

Lantern Pharma Reports First Quarter 2022 Financial Results and Operational Highlights

May 2, 2022

Lantern Pharma's Board of Directors Names Maria Maccecchini, Ph.D. as a Director Nominee to Lantern's Board of Directors

April 25, 2022

Lantern Pharma to Report First Quarter 2022 Operating & Financial Results on May 3rd, 2022 at 4: 30 p.m. ET

April 21, 2022

Lantern Pharma Announces Extension of Existing Share Repurchase Program

March 21, 2022

Lantern Pharma to Present Positive Preclinical Data on the Effectiveness of LP-184 in Brain Metastases at the American Association of Cancer Research (AACR) Annual Meeting

March 13, 2022

Lantern Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Operational Highlights

March 9, 2022

Lantern Pharma Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

March 2, 2022

Lantern Pharma Expands into Additional Pediatric Cancers Through a Collaboration with The Greehey Children's Cancer Research Institute (GCCRI) at University of Texas Health Science Center-San Antonio

February 14, 2022

Lantern Pharma Receives Rare Pediatric Disease and Orpan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT) - an Aggressive and Rapidly Growing Form of Cancer of the Central Nervous System

January 23, 2022

Lantern Pharma Announces Collaboration & Research Agreement with The Danish Cancer Society Research Center to Support Clinical Development of Drug Candidates, LP-100 and LP-184, in Solid Tumors

January 17, 2022

Lantern Pharma Expands Precision Oncology Collaboration with the National Cancer Institute - Accelerating Path to First in Human Clinical Trials for Drug Candidates LP-184 & LP-284

January 11, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 33 decks. Every deck is listed under its year.